Crystalline sodium 3-(2 r-tetrahydrofuryl-methyl )-2-thioxanthine dihydrate
The development of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate addresses the need for stable and bioavailable MPO inhibitor formulations, enabling once-daily dosing and diverse delivery methods for treating MPO-related diseases.
Patent Information
- Application Number
- PCT/US2026/026761
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Existing formulations of 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine require frequent dosing and lack optimal delivery methods for treating a wide range of diseases associated with myeloperoxidase (MPO) activity, and there is a need for stable crystalline forms to enhance bioavailability and delivery options.
Development of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate, which is highly stable and has high aqueous solubility, allowing for once-daily dosing and various delivery forms such as oral, inhalable, and intravenous, while maintaining therapeutic efficacy.
The crystalline form provides improved bioavailability and patient-centric dosing options, effectively inhibiting MPO activity and treating conditions like neuroinflammatory disorders, cardiovascular diseases, and cancers, with reduced pill burden and increased treatment compliance.
Smart Images

Figure US2026026761_12112026_PF_FP_ABST
Abstract
Description
Attorney Docket No. 42443.04033CRYSTALLINE SODIUM 3-(21?-TETRAHYDROFURYL-METHYL)-2- THIOXANTHINE DIHYDRATECROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and all benefit of U.S. Provisional Application No.63 / 801,359, filed May 7, 2025, the entire disclosure of which is fully incorporated herein by reference.FIELD OF THE INVENTION
[0002] The invention relates to crystalline sodium 3 -(2A-tetrahydrofuryl-methyl)- -thioxanthine dihydrate - a novel and surprising crystalline form of 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine. Further the invention also relates to compositions comprising crystalline sodium 3-(2A-tetrahydrofuryl-methyl)-2 -thioxanthine dihydrate and its therapeutic uses.BACKGROUND
[0003] 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine (also known as 3-[[(2R)-tetrahydrofuran-2-yl]methyl]-2-thioxo-7H- purin-6-one) is a potent, irreversible inhibitor of human myeloperoxidase (MPO). MPO is a heme-containing enzyme found predominantly in polymorphonuclear leukocytes (PMNs). MPO is one member of a diverse protein family of mammalian peroxidases that also includes eosinophil peroxidase, thyroid peroxidase, salivary peroxidase, lactoperoxidase, prostaglandin H synthase, and others. 3-(2A-tetrahydrofuryl-methyl -2 -thioxanthine shows a 10-19 fold greater selectivity for myeloperoxidase than for lactoperoxidase and thyroid peroxidase. Mature MPO enzyme is a dimer of identical halves. Each half molecule contains a covalently bound heme that exhibits unusual spectral properties responsible for the characteristic green color of MPO. Cleavage of the disulphide bridge linking the two halves of MPO yields the hemi-enzyme that exhibits spectral and catalytic properties indistinguishable from those of the intact enzyme. The enzyme uses hydrogen peroxide to oxidize chloride to hypochlorous acid. Other halides and pseudohalides (like thiocyanate) are also physiological substrates to MPO.
[0004] PMNs are of particular importance for combating infections. These cells contain MPO, with well-documented microbicidal action. PMNs act non-specifically by phagocytosis to engulf microorganisms, incorporate them into vacuoles, termed phagosomes, which fuse with granules containing myeloperoxidase to form phagolysosomes. In phagolysosomes the enzymatic activityAttorney Docket No. 42443.04033of the myeloperoxidase leads to the formation of hypochlorous acid, a potent bactericidal compound. Hypochlorous acid is oxidizing in itself, and reacts most avidly with thiols and thioethers, but also converts amines into chloramines, and chlorinates aromatic amino acids. Macrophages are large phagocytic cells, which, like PMNs, are capable of phagocytosing microorganisms. Macrophages can generate hydrogen peroxide and upon activation also produce myeloperoxidase. MPO and hydrogen peroxide can also be released to the outside of the cells where the reaction with chloride can induce damage to adjacent tissue.
[0005] The link of myeloperoxidase activity to disease has been implicated in a wide range of diseases. These include neurological diseases with a neuro inflammatory response including multiple sclerosis, Alzheimer's disease, Parkinson's disease and stroke, as well as other inflammatory diseases or conditions like asthma, chronic obstructive pulmonary disease, cystic fibrosis, atherosclerosis, ischemic heart disease, heart failure, inflammatory bowel disease, renal glomerular damage and rheumatoid arthritis. Lung cancer has also been suggested to be associated with high MPO levels and recently MPO has been associated with a mechanism of resistance to immune checkpoint therapy in multiple other cancers. High levels of MPO have also been recognized as a potential cause of male infertility.
[0006] MPO-positive cells are abundant in both blood and inflamed tissue. More specifically, MPO containing macrophages and microglia have been documented in the CNS during disease; multiple sclerosis (Nagra RM, et al. Journal of Neuroimmunology 1997; 78(l-2):97- 107), Parkinson's disease (Choi D-K. et al. J. Neurosci. 2005; 25(28):6594-600) and Alzheimer's disease (Green PS. et al. Journal of Neurochemistry. 2004; 90(3) : 724-33). It is supposed that some aspects of chronic ongoing inflammation result in overwhelming destruction where agents from MPO reactions have an important role.
[0007] MPO is found in active MS lesions and MPO activity is associated with demyelination, a process that damages the protective myelin sheath surrounding the nerve fibers, leading to nerve signal disruption (Maxwell, A. (2014) Chronic Disease, Imaging and InterventiomNeurology). A study involving Japanese patients with relapsing remitting MS were found to have raised MPO levels compared to healthy subjects, with a positive correlation between MPO level and disease severity suggesting a role for an MPO inhibitor in the treatment of MS.
[0008] Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases. COPD is a major public health problem. It is the fourth leading cause of chronic morbidity andAttorney Docket No. 42443.04033mortality in the United States and is projected to rank fifth in 2020 as a worldwide burden of disease. In the UK, the prevalence of COPD is 1.7% in men and 1.4% in women. COPD spans a range of severity from mild to very severe, with the cost of treatment rising rapidly as the severity increases. Levels of MPO in sputum and BAL are much greater in COPD patients than normal, nonsmoking controls (Keatings V.M., Barnes PJ. Am J Respir Crit Care Med 1997; 155:449- 453; Pesci, A. et al. Eur Respir J 1998; 12:380-386). MPO levels are further elevated during exacerbations of the disease (Fiorini G. et al. Biomedicine & Pharmacotherapy 2000; 54:274-278; Crooks S.W. et al. European Respiratory Journal. 15(2): 274-80, 2000). The role of MPO is likely to be more important in exacerbations of COPD (Sharon S. D. et al. Am J Respir Crit Care Med.2001; 163: 349-355).
[0009] In addition to the destructive capacity of MPO, there is a strong clinical link with vascular disease (Baldus S. et al. Circulation 2003; 108: 1440-5). Dysfunctional MPO polymorphisms are associated with a reduced risk of mortality from coronary artery disease (Nikpoor B. et al. Am Heart J 2001; 142: 336), and patients with high serum levels of MPO have increased risk of acute coronary syndrome. The effects of MPO on vascular disease may extend to COPD, since there is strong evidence that the pulmonary vasculature is one of the earliest sites of involvement in the smokers' lung. Striking changes in the intima of the pulmonary arteries have been described which show a dose relationship with smoking (Hale K.A., Niewoehner D.E., Cosio M.G. Am Rev Resp Dis 1980; 122: 273-8). The physiological function of MPO is associated with innate host defense. This role, however, is not critical as most cases of MPO deficient patients have relatively benign symptoms (Parry M.F. et al. Ann Int Med. 1981; 95: 293-301, Yang, K.D., Hill, H.R. Pediatr Infect Dis J. 2001; 20: 889-900). In summary, there is considerable evidence that elevated MPO levels in COPD may contribute to the disease via several mechanisms. A selective inhibitor of MPO would therefore be expected to alleviate both the acute and chronic inflammatory aspects of COPD and may reduce the development of emphysema.
[0010] Several lines of data support a role for MPO in atherosclerosis. An MPO inhibitor should reduce the atherosclerotic burden and / or the vulnerability of existing atherosclerotic lesions and thereby decrease the risk of acute myocardial infarction, unstable angina or stroke, and reduce ischemia / reperfusion injury during acute coronary syndrome and ischemic cerebrovascular events. MPO is expressed in the shoulder regions and necrotic core of human atherosclerotic lesions and active enzyme has been isolated from autopsy specimens of human lesions (Daugherty, A. et al. (1994) J Clin Invest 94(1): 437-44). In eroded and ruptured human lesions, as compared to fatty streaks, an increased number of MPO expressing macrophages have been demonstrated,Attorney Docket No. 42443.04033suggesting a particular role for MPO in acute coronary syndromes (Sugiyama, S. et al. (2001) Am J Pathol 158(3): 879- 91). Patients with established coronary artery disease have higher plasma and leukocyte MPO levels than healthy controls (Zhang, R. et al. (2001) Jama 286(17): 2136-42). Moreover, in two large prospective studies plasma levels of MPO predicted the risk of future coronary events or revascularization (Baldus, S. et al. (2003) Circulation 108(12): 1440-5; Brennan, M. et al. (2003) N Engl J Med 349(17): 1595-604). Total MPO deficiency in humans has a prevalence of 1 in 2000-4000 individuals. These individuals appear principally healthy, but a few cases of severe Candida infection have been reported. Interestingly, MPO deficient humans are less affected by cardiovascular disease than controls with normal MPO levels (Kutter, D. et al. (2000) Acta Haematol 104(1)). A polymorphism in the MPO promoter affects expression leading to high and low MPO expressing individuals. In three different studies, the high expression genotype has been associated with an increased risk of cardiovascular disease (Nikpoor, B. et al. (2001) Am Heart J 142(2): 336-9; Makela, R., P. J. Karhunen, et al. (2003) Lab Invest 83(7): 919-25; Asselbergs, F. W., et al. (2004) Am J Med 116(6): 429-30). Data accumulated during the last ten years indicate that the proatherogenic actions of MPO include oxidation of lipoproteins, induction of endothelial dysfunction via consuming nitric oxide and destabilization of atherosclerotic lesions by activation of proteases (Nicholls, S. J. and S. L. Hazen (2005) Arterioscler Thromb Vase Biol 25(6): 1102-11).
[0011] Recently, several studies have focused on nitro- and chlorotyrosine modifications of LDL and HDL lipoproteins. Since chlorotyrosine modifications in vivo can only be generated by hypochlorous acid produced by MPO, these modifications are regarded as specific markers of MPO activity (Hazen, S. L. and J. W. Heinecke (1997) J Clin Invest 99(9): 2075-81). LDL particles exposed to MPO in vitro become aggregated, leading to facilitated uptake via macrophage scavenger receptors and foam cell formation (Hazell, L. J. and R. Stacker (1993) Biochem J 290 (Pt 1): 165-72). Chlorotyrosine modification of apoAl, the main apolipoprotein of HDL cholesterol, results in impaired cholesterol acceptor function (Bergt, C, S. et al. (2004) Proc Natl Acad Sci U SA; Zheng, L. et al. (2004) J Clin Invest 114(4): 529-41). Systematic studies of these mechanisms have shown that MPO binds to and travels with apoAl in plasma. Moreover, MPO specifically targets those tyrosine residues of apoAl that physically interact with the macrophage ABCA1 cassette transporter during cholesterol efflux from the macrophage (Bergt, C. et al. (2004) J Biol Chem 279(9): 7856- 66; Shao, B. et al. (2005) J Biol Chem 280(7): 5983-93; Zheng et al. (2005) J Biol Chem 280(1): 38-47). Thus, MPO seems to have a dual aggravating role inAttorney Docket No. 42443.04033atherosclerotic lesions, i.e. increasing lipid accumulation via aggregation of LDL particles and decreasing the reverse cholesterol transport via attack on the HDL protein apoAl.
[0012] Obesity, type 2 diabetes and cardiovascular disease are all associated with chronic inflammation and insulin resistance (IR). Insulin resistance can occur in multiple tissues including skeletal, cardiac muscle, adipose, liver and vasculature. Multiple studies have shown a role for inflammation in development of IR. Neutrophils have been implicated in the pathogenesis of IR. Neutrophils, which are abundant in MPO, are activated by a high fat diet and then associate with insulin target tissues (Talukdar, S (2012)NatMed 18:1407-1412). Higher levels ofMPO have also been found in obese individuals compared to those having a healthy body weight. In a rodent model of high fat diet induced microvascular resistance 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine inhibited microvascular IR development and reversed established microvascular IR suggesting neutrophils and IR play a role in both initiating and sustaining high fat diet induced vascular IR. This may suggest therapeutic potential of 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine for the prevention of vascular dysfunction in diseases associated with IR (Chai, W (2019) Endocrinology and Metabolism 317).
[0013] Infertility globally affects approximately 15% of all couples attempting to conceive, with male infertility being the sole cause in 20-30% of cases (Agarwal, A. (2015) Reprod Biol Endocrin 13: 37). Oxidative stress is recognized a common pathway in a significant proportion of infertile men (Aitken, RJ. (2010): 25: 2415-2426). MPO produced by neutrophils plays a role in generating oxidative stress making inhibition of MPO a potential target for therapeutic intervention of male infertility. In an in-vitro model of oxidative stress it was found that 3 -(2A-tetrahydrofuryl-methyl)-2 -thioxanthine had a positive effect on human sperm in the presence of activated neutrophils (Campbell, MJ. (2021) Human Reproduction 36(3): 560-570).US Patent 11,246,870 discloses the use of 3-(2A-tetrahydrofuryl-methyl)-2 -thioxanthine for the treatment of male infertility and is incorporated herein by reference.
[0014] Immunotherapy, such as Immune Checkpoint Therapy (ICT), is considered a standard of care in the treatment of many types of cancers, including cancerous tumors. However, the highly immunosuppressive tumor microenvironment has limited the success of ICT by contributing to resistance. Several studies have demonstrated that MPO contributes to ICT resistance suggesting a possible role for an MPO inhibitor in combination with ICT. MPO inhibitors have recently been shown to enhance the efficacy of ICT in in-vitro and in-vivo models of melanoma (Piwnica-Worms, D. (2022) J Immunother Cancer ll(2):005837) and pancreatic cancer (Liu, TW. (2024) Cancer Immunol Immunother 73(57)).Attorney Docket No. 42443.04033
[0015] 3 -(2A-tetrahydrofuryl-methyl)- -thioxanthine has been dosed to healthy individuals in multiple Phase 1 studies. Immediate release formulations required TID dosing leading to exploration of extended-release formulations. However, these still required BID dosing of 600mg indicating there is a need for new solid forms of 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine that could enable more patient centric formulations with once daily dosing or lower pill burden. Given the wide range of diseases that an MPO inhibitor such as 3-(2A-tetrahydrofuryl-methyl -2 -thioxanthine could potentially be useful for the treatment of it would be beneficial to the healthcare provider to have the option of alternative modes of delivery such as oral solution, inhaled or intravenous that are optimal for both the disease and patient.
[0016] Although therapeutic efficacy is the primary concern for an active pharmaceutical ingredient (API), the chemical composition and solid-state form ( / .< ., the crystalline or amorphous form) of the API can be critical to its pharmacological properties, such as bioavailability, and to its development as a viable drug candidate. Compositions and crystalline forms of some API’s have been used to alter the API’s physicochemical properties. Each composition or crystalline form can have different solid state (physical and chemical) properties. The differences in physical properties exhibited by a novel solid-state form (such as, for example, a polymorph, crystalline salt or cocrystal of an API) may affect pharmaceutical and pharmacological properties such as storage stability, compressibility and density (important in formulation and product manufacturing), and / or solubility and dissolution rates (important factors in determining bioavailability). For example, the rate of dissolution of an active ingredient in a patient's stomach fluid may have therapeutic consequences since it impacts the rate at which an orally administered active ingredient may reach the patient's bloodstream. Because these practical properties are influenced by the solid-state properties, e.g., the crystalline form of the API, they can impact the selection of a particular compound as an API, the ultimate pharmaceutical dosage form, the optimization of manufacturing processes, and absorption in the body.
[0017] Physical properties of an API also have a major influence on the ability to deliver a drug by a desired method. For example, if a drug is delivered by inhalation, physical properties relating to the API as a particle, such as morphology, density, surface energy, charge, hygroscopicity, stability, dispersive properties and / or agglomeration, can come into play. The solid-state form of the API provides opportunities to address, engineer and / or improve upon one or more of such properties and thereby upon methods of delivery.
[0018] Obtaining crystalline forms of an API, when possible, is also extremely useful in drug development. It permits better characterization of the drug candidate’s chemical and physicalAttorney Docket No. 42443.04033properties. Crystalline forms often have better chemical and physical properties than the API in its amorphous state. Moreover, finding the most adequate solid-state form for further drug development can reduce the time and the cost of that development.
[0019] It is known that 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine exists in two polymorphic forms (W02008152420). Existence of multiple polymorphic forms of an API can lead to potential for polymorphic conversion during drug product manufacture and storage, which may impact the drug’s performance. Finding solid forms that do not demonstrate polymorphism is beneficial so as to mitigate any potential risks in later development where polymorphic conversion could impact the drugs shelf-life or clinical benefits.SUMMARY OF THE INVENTION
[0020] The invention relates to crystalline sodium 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate. The invention also relates to pharmaceutical compositions containing crystalline sodium 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate and a pharmaceutically acceptable adjuvant, diluent or carrier. The crystalline sodium 3-(2A-tetrahydrofuryl-methylJ- -thioxanthine dihydrate may be used in the same way as 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine. 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine is an inhibitor of MPO and as such is useful in the treatment or prophylaxis of a disease, disorder, or medical condition associated with increased levels of MPO. The crystalline sodium 3-(2A-tetrahydrofuryl-methyl)- -thioxanthine dihydrate of the invention as such may be useful for the treatment of the diseases, disorders and medical conditions associated with such properties.BRIEF DESCRIPTION OF THE FIGURES
[0021] Fig. 1 shows the experimental XRPD pattern of the crystalline sodium 3-(2A-tetrahydrofuryl-methyl)- -thioxanthine dihydrate.
[0022] Fig. 2 shows the thermal gravimetric analysis (TGA) trace of the crystalline sodium 3 -(2 / -tetrahydrofuryl -methyp-2 -thioxanthine dihydrate.
[0023] Fig. 3 shows he1H NMR spectrum of the crystalline sodium 3-(2A-tetrahydrofuryl-methyl)- -thioxanthine dihydrate.
[0024] Fig. 4 shows the experimental infrared Spectrum of the crystalline sodium 3-(2A-tetrahydrofuryl-methylJ- -thioxanthine dihydrate.
[0025] Fig. 5 shows the moisture sorption isotherm graph obtained for the crystalline sodium 3 -(2A-tetrahydrofuryl-methyl)- -thioxanthine dihydrate.Attorney Docket No. 42443.04033DESCRIPTION OF THE INVENTION
[0026] The invention relates to the novel and surprising crystalline 3-(2 / ?-tetrahydrofuryl-methyp-2 -thioxanthine, specifically crystalline sodium 3-(2A-tetrahydrofuryl-methylJ-2-thioxanthine dihydrate. The crystalline sodium 3 -(2R-tetrahydrofuryl-methylJ-2 -thioxanthine dihydrate of the invention is highly stable under normal storage conditions and has high aqueous solubility. Dehydration of the crystalline sodium 3 -(2A-tetrahydrofuryl-methyl - -thioxanthine dihydrate under vacuum results in a loss of crystallinity and amorphization, which upon reexposure to humidity results in recrystallisation back to the crystalline sodium 3-(2A-tetrahydrofuryl-methylJ-2 -thioxanthine dihydrate of the invention, demonstrating the requirement of the two water molecules to obtain the stable crystalline sodium salt.
[0027] Crystalline sodium 3 -(2A-tetrahydrofuryl-methyl -2 -thioxanthine dihydrate, its preparation and characterization are described in the examples below and shown in the figures. The crystalline sodium 3-[(2R)-tetrahydrofuran-2-ylmethyl]-2-thioxanthine dihydrate is a novel crystalline sodium dihydrate that is distinct from other forms of 3-[(2R)-tetrahydrofuran-2-ylmethyl]-2-thioxanthine and has unique X-ray powder diffraction pattern, water stoichiometry, and solid-state behavior.
[0028] Crystalline sodium 3 -(2A-tetrahydrofuryl-methyl -2 -thioxanthine dihydrate of the invention may be administered and used in a similar way as the compounds described in W02003089430, W02008152420 and US 11,246,870, which are incorporated here by reference. Crystalline sodium 3 -(2A-tetrahydrofuryl-methyl -2 -thioxanthine dihydrate may be further processed before formulating into a suitable pharmaceutical formulation. For example, the crystalline form may be milled or ground into smaller particles.
[0029] Another aspect of the invention provides a pharmaceutical formulation including crystalline sodium 3 -(2A-tetrahydrofuryl-methyl -2 -thioxanthine dihydrate in admixture with a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable diluent, or a pharmaceutically acceptable carrier as well as other a pharmaceutically acceptable excipients known in the art.
[0030] Methods of Treatment
[0031] The invention provides a method of treatment of a disease, disorder, or medical condition where 3 -(2 / -tetrahydrofuryl -methyl )-2-thioxanthine is required or desired, which method includes administering a therapeutically effective amount of crystalline sodium 3-(2A-tetrahydrofuryl-methylJ-2 -thioxanthine dihydrate to a subject in need of such treatment.Attorney Docket No. 42443.04033
[0032] The invention also provides the use of crystalline sodium 3-(2A-tetrahydrofuryl-methyp-2-thioxanthine dihydrate in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme MPO is beneficial.
[0033] Another aspect of the invention provides the use of crystalline sodium 3-(2A-tetrahydrofuryl-methylJ-2 -thioxanthine dihydrate in the manufacture of a medicament, for the treatment or prophylaxis of neuro inflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease, heart failure, diseases associated with insulin resistance and respiratory disorders such as chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis or cystic fibrosis, idiopathic male infertility, diseases associated with insulin resistance and prevention of resistance to Immune Checkpoint Therapy in the treatment of cancers, including cancerous tumors.
[0034] The invention further provides the use of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate in the manufacture of a medicament, for the treatment or prophylaxis of multiple sclerosis. Treatment may include slowing progression of disease.
[0035] Another aspect of the invention relates to the use of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate in the manufacture of a medicament, for the treatment or prophylaxis of Parkinson's disease. Treatment may include slowing progression of disease.
[0036] The invention further relates to the use of crystalline sodium 3-(2A-tetrahydrofuryl-methyp-2-thioxanthine dihydrate in the manufacture of a medicament, for the treatment or prophylaxis of atherosclerosis by preventing and / or reducing the formation of new atherosclerotic lesions or plaques and / or by preventing or slowing progression of existing lesions and plaques.
[0037] Another aspect of the invention provides use of crystalline sodium 3-(2A-tetrahydrofuryl-methylJ-2 -thioxanthine dihydrate in the manufacture of a medicament, for the treatment or prophylaxis of atherosclerosis by changing the composition of the plaques to reduce the risk of plaque rupture and atherothrombotic events.
[0038] In another aspect the invention provides the use of crystalline sodium 3-(2A-tetrahydrofuryl-methylJ-2 -thioxanthine dihydrate in the manufacture of a medicament, for the treatment or idiopathic male infertility. Treatment may include an improvement in a patient’s fertility or a decrease in the risk of infertility.
[0039] Another aspect of the invention provides the use of crystalline sodium 3-(2A-tetrahydrofuryl-methylJ-2 -thioxanthine dihydrate in the manufacture of a medicament, for theAttorney Docket No. 42443.04033treatment or prophylaxis of respiratory disorders, such as chronic obstructive pulmonary disease. Treatment may include slowing progression of disease.
[0040] The invention also provides the use of crystalline sodium 3-(2A-tetrahydrofuryl-methyp-2-thioxanthine dihydrate in the manufacture of a medicament, for the prevention of resistance to Immune Checkpoint Therapy in the treatment of certain cancers. Treatment may include a reduction in resistance to ICT drugs.
[0041] Another aspect of the invention provides a method of treating, or reducing the risk of, diseases or conditions in which inhibition of the enzyme MPO is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of crystalline sodium 3 -(2A-tetrahydrofuryl-methyl / - -thioxanthine dihydrate.
[0042] Another aspect of the invention provides a method of treating, or reducing the risk of, neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders or peripheral artery disease, or heart failure or respiratory disorders, such as chronic obstructive pulmonary disease (COPD), in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of crystalline sodium 3 -(2A-tetrahydrofuryl-methyl - -thioxanthine dihydrate. According to one embodiment of the invention the COPD is bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis or cystic fibrosis
[0043] The invention also provides a method of treating, or reducing the risk of, multiple sclerosis in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of crystalline sodium 3-(2A-tetrahydrofuryl-methyl / - -thioxanthine dihydrate.
[0044] In another embodiment, the invention is a method of treating, or reducing the risk of, Parkinson's disease in a person suffering from or at risk of, the disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of crystalline sodium 3 -(2A-tetrahydrofuryl-methyl - -thioxanthine dihydrate.
[0045] The invention also relates to a method of treating, or reducing the risk of atherosclerosis by preventing and / or reducing the formation of new atherosclerotic lesions or plaques and / or by preventing or slowing progression of existing lesions and plaques in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of crystalline sodium 3-(2 / ?-tetrahydrofuryl-methyp-2 -thioxanthine dihydrate.Attorney Docket No. 42443.04033
[0046] Another embodiment of the invention is a method of treating, or reducing the risk of atherosclerosis by changing the composition of the plaques so as to reduce the risk of plaque rupture and atherothrombotic events in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of crystalline sodium 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate.
[0047] The invention further provides a method of treating, or reducing the risk of, idiopathic male infertility in a person suffering from or at risk of, the condition, wherein the method comprises administering to the person a therapeutically effective amount of crystalline sodium 3-(2A-tetrahydrofuryl-methyl)- -thioxanthine dihydrate.
[0048] The invention also relates to a method of treating, or reducing the risk of, resistance to Immune Checkpoint Therapy in a person undergoing ICT cancer treatment, wherein the method comprises administering to the person a therapeutically effective amount of crystalline sodium 3-(2A-tetrahydrofuryl-methyl)- -thioxanthine dihydrate.
[0049] Pharmaceutical Compositions Containing Crystalline Sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate
[0050] The invention relates to pharmaceutical compositions comprising, consisting essentially of, or consisting of a therapeutically effective amount of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention and a pharmaceutically acceptable excipient (also known as a pharmaceutically acceptable carrier). As mentioned above, these pharmaceutical compositions are therapeutically useful to treat or prevent diseases, disorders, or conditions associated with inhibition of the enzyme MPO, such as those discussed above. A pharmaceutical composition of the invention may be a solid dosage form made with crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention.
[0051] A pharmaceutical composition of the invention may be in any pharmaceutical form which contains crystalline sodium 3 -(2R-tetrahydrofuryl-methyl)-2 -thioxanthine dihydrate of the invention. The pharmaceutical composition may be, for example, a tablet, a capsule, an oral composition, a sublingual composition, an injectable composition, a topical composition, an inhalable composition, or a transdermal composition.
[0052] The pharmaceutical compositions generally contain, for example, about 0.1% to about 99.9% by weight of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention, for example, about 0.5% to about 99.5% by weight of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention and, for example, 99.5% to 0.5% by weight of at least one suitable pharmaceutical excipient or solvent. In oneAttorney Docket No. 42443.04033embodiment, the composition may be between about 5% and about 75% by weight of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention with the rest being at least one suitable pharmaceutical excipient, solvent, or other adjuvant, as discussed below.
[0053] Myeloperoxidase inhibitors are generally used in the range of 2.5-5000 mg / m2. The body surface area of the animal, or a unit dose of about 0.05-100 mg / kg, is administered to a warmblooded animal, and this typically provides a therapeutically effective dose. Unit dosage forms such as tablets or capsules usually contain, for example, 0.1 to 500 mg of active ingredient. The daily dosage will necessarily vary with the host treated, the particular route of administration, any treatments co-administered, and the severity of the disease being treated. Thus, a practitioner treating any particular patient may determine the optimal dosage. A "therapeutically effective amount of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention" is that which correlates to a therapeutic effect and may for example, be about 25 mg -about 500 mg, about 50 mg - about 400 mg, about 75 mg - about 300 mg, or preferably about 100 mg - about 300 mg, administered in a single dose or multiple doses, e.g. two to three times, per day. The actual amount required for treatment of any particular disease, disorder, or condition for any particular patient may depend upon a variety of factors including, for example, the particular disease, disorder, or condition being treated; the disease state being treated and its severity; the specific pharmaceutical composition employed; the age, body weight, general health, sex, and diet of the patient; the mode of administration; the time of administration; the route of administration; the rate of excretion; the duration of the treatment; any drugs used in combination or coincidental with the specific compound employed; and other such factors well known in the medical arts. These factors are discussed in Goodman and Gilman’s “The Pharmacological Basis of Therapeutics”, Tenth Edition, A. Gilman, J. Hardman and L. Limbird, eds., McGraw-Hill Press, 155-173, 2001, which is incorporated herein by reference.
[0054] Depending on the type of pharmaceutical composition, the pharmaceutically acceptable excipient may be chosen from any one or a combination of excipients known in the art. The choice of pharmaceutically acceptable excipient depends upon the pharmaceutical form and the desired method of administration to be used. For a pharmaceutical composition of the invention, that is one containing crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention, an excipient should be chosen that maintains its crystalline form. In other words, the excipient should not substantially alter crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention. Nor should the excipient be otherwise incompatible with crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate ofAttorney Docket No. 42443.04033the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition.
[0055] The pharmaceutical compositions of the invention may be prepared by methods known in the pharmaceutical formulation art, for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990), which is incorporated herein by reference. In a solid dosage form, crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention may be admixed with at least one pharmaceutically acceptable excipient such as, for example, sodium citrate or dicalcium phosphate or (a) fillers or extenders, such as, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, such as, for example, cellulose derivatives, starch, alginates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, such as, for example, glycerol, (d) disintegrating agents, such as, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retarders, such as, for example, paraffin, (f) absorption accelerators, such as, for example, quaternary ammonium compounds, (g) wetting agents, such as, for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like (h) adsorbents, such as, for example, kaolin and bentonite, and (i) lubricants, such as, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
[0056] Pharmaceutically acceptable adjuvants known in the pharmaceutical formulation art may also be used in the pharmaceutical compositions of the invention. These include, but are not limited to, preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms may be ensured by inclusion of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.
[0057] Solid dosage forms as described above may be prepared with coatings and shells, such as enteric coatings and others, as is known in the pharmaceutical art. They may contain pacifying agents and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Non-limiting examples ofAttorney Docket No. 42443.04033embedded compositions that may be used are polymeric substances and waxes. The active compounds may also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
[0058] Suspensions, in addition to the active compounds, may contain suspending agents, such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
[0059] Methods of administering crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention topically to the lung may involve a dry powder inhaler formulation of respirable particles comprised of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention, which the patient being treated inhales. It is common for a dry powder formulation to include carrier particles, to which particles of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention can adhere to. The carrier particles may be of any acceptable pharmacologically inert material or combination of materials. For example, the carrier particles may be composed of one or more materials selected from sugar alcohols; polyols, for example sorbitol, mannitol or xylitol, and crystalline sugars, including monosaccharides and disaccharides; inorganic salts such as sodium chloride and calcium carbonate; organic salts such as sodium lactate; and other organic compounds such as urea and polysaccharides, for example cyclodextrins and dextrins. The carrier particles may be a crystalline sugar, for example, a monosaccharide, such as glucose or arabinose, or a disaccharide, such as maltose, saccharose, dextrose, or lactose.
[0060] In addition to the topical method of administration described above, there are various methods of administering crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention systemically by such methods. One such means would involve an aerosol suspension of respirable particles comprised of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention, which the patient being treated inhales. Crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention would be absorbed into the bloodstream via the lungs in a pharmaceutically effective amount. The respirable particles can be liquid or solid, with a particle size sufficiently small to pass through the mouth and larynx upon inhalation.
[0061] Because the crystalline form of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2 -thioxanthine dihydrate of the invention may be maintained during preparation, solid dosage forms are one embodiment of the pharmaceutical composition of the invention. Dosage forms forAttorney Docket No. 42443.04033oral administration, which includes capsules, tablets, pills, powders, granules, and suspensions, may be used. Dosage forms for pulmonary administration, which includes metered dose inhaler, dry powder inhaler, or aerosol formulations, may be used. In such solid dosage forms, the active compounds may be mixed with at least one inert, pharmaceutically acceptable excipient (also known as a pharmaceutically acceptable carrier).
[0062] Crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention may also be used to formulate liquid or injectable pharmaceutical compositions. Administration of crystalline sodium 3 -(2R-tetrahydrofuryl-methyl)-2 -thioxanthine dihydrate of the invention in pure form or in an appropriate pharmaceutical composition may be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration may be, for example, orally, sublingually, buccally, nasally, pulmonary, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intrasy stemically, or, ophthalmically, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, such as, for example, in unit dosage forms suitable for simple administration of precise dosages. One route of administration may be oral or sublingual administration, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the condition to be treated.
[0063] The invention also relates to a method of preparing a liquid pharmaceutical composition comprising the step of dissolving crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2 -thioxanthine dihydrate of the invention in a pharmaceutically acceptable solvent and to liquid pharmaceutical compositions prepared according to that method. As discussed above, liquid pharmaceutical compositions of the invention may be administered orally, parenterally (including by inhalation), and intravenously.
[0064] The invention provides a pharmaceutical formulation comprising a therapeutically effective amount of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme MPO is beneficial.
[0065] Another aspect of the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of neuro inflammatory disorders.Attorney Docket No. 42443.04033
[0066] In another embodiment the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of multiple sclerosis, idiopathic male infertility, certain cancers, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and heart failure and respiratory disorders, such as chronic obstructive pulmonary disease.
[0067] The invention also provides a pharmaceutical formulation comprising a therapeutically effective amount of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of atherosclerosis by preventing and reducing the formation of new atherosclerotic lesions and / or plaques and / or by preventing or slowing progression of existing lesions and plaques.
[0068] Another aspect of the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of atherosclerosis by changing the composition of the plaques so as to reduce the risk of plaque rupture and atherothrombotic events.
[0069] The invention further relates to therapies for the treatment of: Neurodegenerative Disorder(s) including but not limited to Alzheimer's Disease (AD), Dementia, Cognitive Deficit in Schizophrenia (CDS), Mild Cognitive Impairment (MCI), Age- Associated Memory Impairment (AAMI), Age-Related Cognitive Decline (ARCD), Cognitive Impairment No Dementia (CIND), Multiple Sclerosis, Parkinson's Disease (PD), postencephalitic parkinsonism, Huntington's Disease, amyotrophic lateral sclerosis (ALS), motor neuron diseases (MND), Multiple System Atrophy (MSA), Corticobasal Degeneration, Progressive Supranuclear Paresis, Guillain-Barre Syndrome (GBS), and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Dementia includes, but is not limited to, Down syndrome, vascular dementia, dementia with Lewy bodies, HIV dementia, Frontotemporal dementia Parkinson's Type (FTDP), Pick's Disease, Niemann-Pick's Disease, traumatic brain injury (TBI), dementia pugilistica, Creutzfeld- Jacob Disease and prion diseases.
[0070] The invention further relates to therapies for the treatment of: Neuroinflammatory Disorder(s)including but not limited to Multiple Sclerosis (MS), Parkinson's disease, Multiple System Atrophy (MSA), Corticobasal Degeneration, Progressive Supranuclear Paresis, Guillain-Attorney Docket No. 42443.04033Barre Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP). Multiple sclerosis (MS) includes Relapse Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), and Primary Progressive Multiple Sclerosis (PPMS).
[0071] The invention also relates to therapies for the treatment of: Cognitive Disorder(s) including but not limited to a) Dementia, including but not limited to Alzheimer's Disease (AD), Down syndrome, vascular dementia, Parkinson's Disease (PD), postencephelatic parkinsonism, dementia with Lewy bodies, HIV dementia, Huntington's Disease, amyotrophic lateral sclerosis (ALS), motor neuron diseases (MND), Frontotemporal dementia Parkinson's Type (FTDP), progressive supranuclear palsy (PSP), Pick's Disease, Niemann-Pick's Disease, corticobasal degeneration, traumatic brain injury (TBI), dementia pugilistica, Creutzfeld- Jacob Disease and prion diseases; b) Cognitive Deficit in Schizophrenia (CDS); c) Mild Cognitive Impairment (MCI); d) Age- Associated Memory Impairment (AAMI); e) Age-Related Cognitive Decline (ARCD); f) Cognitive Impairment No Dementia (CIND).
[0072] In other embodiments the invention relates to therapies for the treatment of: Attention-Deficit and Disruptive Behavior Disorder(s) including but not limited to attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD) and affective disorders.
[0073] The invention also relates to the treatment of the diseases and conditions below which may be treated with crystalline sodium 3 -(2A-tetrahydrofuryl-methyl)-2 -thioxanthine dihydrate: respiratory tract: obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti -neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus; bone and joints:Attorney Docket No. 42443.04033arthritides associated with or including osteoarthritis / osteoarthrosis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and low back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy; septic arthritis and other infection- related arthopathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal-induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositits and polymyositis; polymalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; low back pain; Familial Mediterranean fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; drug-induced arthalgias, tendonititides, and myopathies;
[0074] The invention further relates to combination therapies wherein crystalline sodium 3 -(2A-tetrahydrofuryl-methyl)- -thioxanthine dihydrate, or a pharmaceutical composition or formulation comprising crystalline sodium 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate is administered concurrently or sequentially with therapy and / or an agent for the treatment of any one of cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease.
[0075] Crystalline sodium 3-(2A-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate may be administered in association with compounds from one or more of the following groups: 1) antiinflammatory agents, for example a) NSAIDs (e.g. acetylsalicylic acid, Ibuprofen, naproxen, flurbiprofen, diclofenac, indometacin); b) leukotriene synthesis inhibitors (5-LO inhibitors e.g.AZD4407,Zileuton, licofelone, CJ13610, CJ13454; FLAP inhibitors e.g. BAY-Y-1015, DG-031, MK591, MK886, A81834; LTA4 hydrolase inhibitors e.g. SC56938, SC57461A); c) leukotriene receptor antagonists ( e.g.CP195543, amelubant, LY293111, accolate, MK571); 2) anti-hypertensive agents, for example a) beta-blockers (e.g. metoprolol, atenolol, sotalol); b) angiotensin converting enzyme inhibitors (e.g. captopril, ramipril, quinapril, enalapril); c) calciumAttorney Docket No. 42443.04033channel blockers (e.g.verapamil, diltiazem, felodipine, amlodipine); d) angiotensin II receptor antagonists (e.g.irbesartan, candesartan,telemisartan, losartan); 3) anti-coagulantia, for example a) thrombin inhibitors (e.g.ximelagatran), heparines, factor Xa inhibitors; b) platelet aggregation inhibitors (e.g.clopidrogrel, ticlopidine, prasugel, AZ4160); 4) modulators of lipid metabolism, for example a) insulin sensitizers such as PPAR agonists (e.g.pioglitazone, rosiglitazone, Galida, muraglitazaar, gefemrozil, fenofibrate); b) HMG-CoA reductase inhibitors, statins(e.g. simvastatin, pravastatin, atorvaststin, rosuvastatin, fluvastatin); c) cholesterol absorption inhibitors (e.g.ezetimibe); d) IBAT inhibitors (e.g. AZD-7806); e) LXR agonists (e.g. GW-683965A, T-0901317); f) FXR receptor modulators; g) phospholipase inhibitors; h) anti-anginal agents, for example, nitrates and nitrites; and i) modulators of oxidative stress, for example, anti-oxidants (e.g. probucol, AG1067).
[0076] For the avoidance of doubt, "treatment" includes the therapeutic treatment, as well as the prophylaxis, of a condition.
[0077] Crystalline sodium 3-(2A-tetrahydrofuryl-methyl)-2 -thioxanthine dihydrate has the advantage that it has not shown any signs of polymorphism during handling or long-term storage, with no change in solid form after storage under ambient condition for 6 months. Thus, the compound may be stable when stored for prolonged periods.
[0078] Examples
[0079] The following analytical methods were used to characterize the novel and surprising crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention:
[0080] X-Ray Powder Diffraction (XRPD) Characterization: X-ray powder diffraction patterns for the samples were acquired on a Malvern Panalytical Empyrean Alpha- 1 diffractometer using Cu Ka radiation (45 kV, 40 mA) in reflection geometry with a 9-29 goniometer fitted with a Ge (111) Johansson monochromator. A programmable divergence slit in automatic mode with an observed length of 10 mm, with a 10 mm fixed incident beam mask and 0.04 rad Soller slits were used on the incident beam. A PIXcel1Ddetector, placed on the diffracted beam, was fitted with a programmable antiscatter slit (in automatic mode with an observed length of 10 mm) and 0.04 rad Soller slits. The data were collected with the detector in scanning line mode with an active length of 3.3482°. The software used for data collection was Data Collector and the data analyzed and presented using HighScore Plus. Samples were run under ambient conditions as flat plate specimens using powder as received. The sample was prepared on a polished, zero-backgroundAttorney Docket No. 42443.04033(510) silicon wafer by gently pressing onto the flat surface or packed into a cut cavity. The sample was rotated in its own plane using 2 seconds per rotation.
[0081] Thermo-Gravimetric Analysis (TGA): TGA data were collected on a PerkinElmer Pyris 1 TGA equipped with a 20 position auto-sampler. The instrument was calibrated using a certified weight and certified Alumel and Perkalloy for temperature. A predefined amount of the sample, 1-5 mg, was loaded onto a pre-tared aluminium crucible and was heated at 20 °C / min from ambient temperature to 400 °C. A nitrogen purge at 20 ml / min was maintained over the sample. The instrument control, data acquisition and analysis were performed with Pyris Software v9.0.1.0203.
[0082] Solution Proton Nuclear Magnetic Resonance I'H-NMR):1H-NMR spectra were collected on a Bruker 400 MHz instrument equipped with an auto-sampler and controlled by a Avance NEO nanobay console. Samples were prepared in the appropriate solvent. Automated experiments were acquired using ICON-NMR configuration within Topspin software, using standard Bruker-loaded experiments (1H).
[0083] Karl Fischer Titration: The water content of the samples was measured on a Metrohm 874 Oven Sample Processor at 150 °C with 851 Titrano Coulometer, using Hydranal Coulomat AG oven reagent and nitrogen purge. Weighed solid samples were introduced into a sealed sample vial. Approximately 10 mg of sample was used per titration and duplicate determinations were made. An average of these results is presented unless otherwise stated. Data collection and analysis were performed using Tiamo software.
[0084] Gravimetric Vapor Sorption (GVS): Sorption isotherms were obtained using a SMS DVS Intrinsic moisture sorption analyzer, controlled by DVS Intrinsic Control software. The sample temperature was maintained at 25 °C by the instrument controls. The humidity was controlled by mixing streams of dry and wet nitrogen, with a total flow rate of 200 ml / min. The relative humidity was measured by a calibrated Rotronic probe (dynamic range of 1.0 - 100 %RH), located near the sample. The weight change (mass relaxation) of the sample as a function of %RH was constantly monitored by a microbalance (accuracy ±0.005 mg)._Typically, 5 - 30 mg of sample was placed in a tared mesh stainless steel basket under ambient conditions. The sample was loaded and unloaded at 40 %RH and 25 °C (typical room conditions). A moisture sorption isotherm was performed using the method parameters described in Table 1 (2 scans per complete cycle). The standard isotherm was performed at 25 °C at 10 %RH intervals over a 0 - 90 %RH range. Typically, a double cycle (4 scans) was carried out. Data analysis was carried out within MicrosoftAttorney Docket No. 42443.04033Excel using the DVS Analysis Suite. The sample was recovered after completion of the isotherm and re-analyzed by XRPD.Table 1Parameter ValueAdsorption - Scan 1 40 - 90Desorption, Adsorption - Scan 2 90 - 0, 0 - 40Intervals (%RH) 10Number of Scans 4Flow rate (ml / min) 200Temperature (°C) 25Stability (°C / min) 0.2Sorption Time (hours) 6-hour time outNumber of cycles 2
[0085] Fourier-Transform Infrared Spectroscopy (FT-IR): FT-IR data were collected on a Perkin-Elmer Spectrum 3 fitted with a universal ATR sampling accessory using a 1 Bounce Diamond / ZnSe crystal. Spectra were collected 4000 - 650 cm’1over 16 scans. The data were collected using Spectrum IR software and processed using ACD Spectrus Processor.
[0086] Example 1: Crystalline Sodium 3-(21?-Tetrahydrofuryl-Methyl)-2- Thioxanthine Dihydrate
[0087] 1.1 Preparation of Crystalline Sodium 3-(21?-Tetrahydrofuryl-Methyl)-2- Thioxanthine Dihydrate
[0088] The batch of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate used for characterization was prepared as follows:
[0089] 3-(2R-Tetrahydrofuryl-methyl)-2 -thioxanthine (200 mg, 0.79 mmol) was placed in a glass vial and sodium hydroxide (32 mg, 0.79 mmol) dissolved in ethanol (2 ml) was added. The resulting solution was allowed to evaporate resulting in a solid product that was analyzed as below.
[0090] 1.2 XRPD Characterization of Crystalline Sodium 3-(21?-Tetrahydrofuryl- Methyl)-2-Thioxanthine Dihydrate
[0091] The experimental XRPD pattern of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate is shown in FIG. 1. Table 2 lists the angles, °29 ± 0.2 °29, and d-spacing of the peaks identified in the experimental XRPD pattern of FIG. 1. The entire list ofAttorney Docket No. 42443.04033peaks, or a subset thereof, may be sufficient to characterize the cocrystal, as well as by an XRPD pattern substantially similar to FIG. 1. For example, crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate may be characterized by at least two, at least three, at least four, or all of the peaks selected from the peaks at 5.8, 6.9, 8.6, 10.8, and 11.6 °29 ± 0.2°29.Table 2Angle d Value Intensity°20 ± 0.2 °20 Angstrom %5.8 15.15 100.0%6.9 12.72 2.5%8.6 10.30 27.1%10.8 8.22 3.4%11.6 7.61 20.2%12.6 7.02 2.3%13.9 6.38 2.0%15.2 5.84 7.7%15.3 5.78 8.8%15.6 5.66 3.8%16.4 5.39 3.6%17.5 5.07 6.0%19.1 4.64 13.5%19.3 4.60 3.2%19.8 4.49 5.1%20.8 4.26 16.9%21.2 4.19 2.7%23.3 3.81 20.1%23.6 3.77 6.0%23.8 3.74 17.3%24.0 3.70 2.9%24.8 3.59 6.9%25.3 3.52 5.6%25.6 3.48 7.3%25.8 3.45 10.8%Attorney Docket No. 42443.0403326.0 3.43 3.6%26.4 3.38 4.5%26.8 3.32 7.5%27.1 3.29 3.0%27.9 3.19 3.8%28.3 3.15 4.2%29.0 3.07 13.3%29.6 3.01 22.5%30.4 2.94 8.2%30.6 2.92 3.8%32.5 2.75 4.5%32.7 2.74 2.9%34.8 2.58 3.2%35.0 2.56 4.0%37.6 2.39 6.3%38.7 2.33 5.5%39.1 2.30 4.2%40.3 2.23 4.8%41.5 2.18 3.7%
[0092] 1.3 TGA of Crystalline Sodium 3-(21?-Tetrahydrofuryl-Methyl)-2- Thioxanthine Dihydrate
[0093] The thermal gravimetric analysis (TGA) trace, FIG. 2, of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2 -thioxanthine dihydrate shows a weight loss of 11.5 % between 40 and 160 °C which corresponds to a stoichiometry of 2 moles of water.
[0094] 1.41H NMR Spectrum of Crystalline Sodium 3-(21?-Tetrahydrofuryl-Methyl)- 2-Thioxanthine Dihydrate
[0095] TheJH NMR spectrum of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate shown in FIG. 3, displays the following peaks:JH NMR (400MHz, MeOD) 6: 1.88 (2H), 1.97 (1H), 2.09 (1H), 3.73 (1H), 3.99 (1H), 4.50 (2H), 4.76 (2H) and 7.48 (1H).
[0096] 1.5 Karl Fischer Titration of Crystalline Sodium 3-(21?-Tetrahydrofuryl- Methyl)-2-Thioxanthine DihydrateAttorney Docket No. 42443.04033
[0097] Karl Fischer analysis of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate indicated that the sample contained 12% water, which is equivalent to a stoichiometry of 2 moles of water.
[0098] 1.6 Infrared Spectrum of Crystalline Sodium 3-(21?-Tetrahydrofuryl-Methyl)- 2-Thioxanthine Dihydrate
[0099] The experimental infrared Spectrum of crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate is shown in FIG. 4. The significant peaks identified in the experimental infrared spectrum of FIG. 4 are 3601, 3496, 3039, 2937, 2862, 2162, 1980, 1660, 1523, 1459, 1414, 1403, 1390, 1318, 1294, 1267, 1235, 1200, 1173, 1157, 1071, 1049, 988, 952, 883, 835, 769, 730, 695, 681, and 656 cm’1± 1 cm’1. The entire list of peaks, or a subset thereof, may be sufficient to characterize crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate, as well as by an infrared pattern substantially similar to FIG. 4.[000100] 1.6 Gravimetric Vapour Sorption (GVS) Analysis of Crystalline Sodium 3-(2R- Tetrahydrofuryl-Methyl)-2-Thioxanthine Dihydrate[000101] The moisture sorption isotherm graph obtained for crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate is shown in FIG. 5. The crystalline AZD5904 sodium dihydrate salt was found to reversibly absorb 4.8 % w / w across the 90% humidity range at 25° C, with an initial uptake of 4.3% w / w between 40 and 90 % humidity range and evidence of hysteresis across this humidity range. XRPD analysis of the sample post GVS analysis confirmed that the crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate had retained its original crystalline form with no evidence of solid-state form conversion.[000102] 1.7 Storage of Crystalline Sodium 3-(21?-Tetrahydrofuryl-Methyl)-2- Thioxanthine Dihydrate with respect to solid-state form conversion[000103] Crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate was stored in a glass vial under ambient conditions for 6 months, after which time analysis by XRPD confirmed that the crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate had retained its original crystalline form with no evidence of solid-state form conversion.[000104] Crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate (20mg) was placed in a sealed container at 40 ° C and 75% relative humidity and stored under these conditions for one week. Analysis by XRPD after this time indicated that the crystalline sodium 3 -(2R-tetrahydrofuryl-methyl)-2 -thioxanthine dihydrate had retained its original crystalline form with no evidence of solid-state form conversion.Attorney Docket No. 42443.04033[000105] The crystalline sodium 3 -(2R-tetrahydrofuryl-methyl)-2 -thioxanthine dihydrate was stored under vacuum at 40 °C for 48 hours. XRPD analysis of the sample after this time showed that the compound had lost its crystallinity resulting in an amorphous solid-state form. Based on the TGA, Karl Fischer Titration, and GVS discussed above, this is understood to be from the loss of the H2O molecules of hydration. The resulting amorphous sample was then placed in a sealed container at 40° C and 75% relative humidity and stored under these conditions for 3 days. XRPD analysis of the sample after this time demonstrated an XRPD pattern similar to that shown in FIG. 1, indicating reconversion back to the original crystalline form of the crystalline sodium 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine dihydrate of the invention.
Claims
1. Attorney Docket No. 42443.04033CLAIMSThe claimed invention is:
1. Crystalline sodium 3-(2 / ?-tetrahydrofuryl-methyp-2 -thioxanthine dihydrate.
2. The crystalline sodium 3-(2 / ?-tetrahydrofuryl-methyp-2-thioxanthine dihydrate of claim 1, characterized:an X-ray powder diffraction pattern having at least two peaks selected from the peaks at 5.8, 6.9, 8.6, 10.8, and 11.6 °26 ± 0.2o26;an X-ray diffraction pattern substantially similar to FIG. 1; oran IR spectrum substantially similar to FIG. 4.
3. A pharmaceutical composition comprising the crystalline sodium 3-(2 / ?-tetrahydrofuryl-methyp-2 -thioxanthine dihydrate of claim 1 or claim 2 and a pharmaceutically acceptable adjuvant, diluent or carrier.
4. A method for treating or preventing a disease, disorder or medical condition associated with increased levels of MPO comprising the step of:administering to a subject in need thereof a therapeutically effective amount of the crystalline sodium 3-(27?-tetrahydrofuryl-methyl - -thioxanthine dihydrate of claim 1 or claim 2.
5. A method for treating or preventing a disease, disorder or medical condition associated with increased levels of MPO comprising the step of:administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 3.
